Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[L-DOPA-induced dyskinesia]

P. Derkinderen1, M. Vidailhet

  • 1Service de Neurologie, Hôpital Saint-Antoine, 75012 Paris.

Revue Neurologique
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Levodopa (L-DOPA)-induced dyskinesias affect many Parkinson's patients, often starting as foot dystonia. Understanding risk factors and movement patterns is crucial for managing these involuntary movements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study.

Revue neurologique·2026
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
See all related articles

Area of Science:

  • Neurology
  • Movement Disorders
  • Pharmacology

Background:

  • Levodopa (L-DOPA) is a primary treatment for Parkinson's disease.
  • L-DOPA-induced dyskinesias (LID) are a common and debilitating complication.
  • Approximately one-third of patients develop LID within five years of L-DOPA therapy.

Purpose of the Study:

  • To review the clinical characteristics and potential pathophysiology of L-DOPA-induced dyskinesias.
  • To identify key variables associated with LID development.
  • To discuss the classification and assessment of dyskinesias.

Main Methods:

  • Literature review of studies on L-DOPA-induced dyskinesias.
  • Analysis of clinical data and proposed pathophysiological mechanisms.

Related Experiment Videos

  • Examination of existing dyskinesia rating scales.

    • Main Results:

    • Younger age of onset, disease severity, L-DOPA dose, and treatment duration are significant risk factors for LID.
    • Dyskinesias often manifest initially as focal dystonia, typically in the foot.
    • Common classifications include off dystonia, diphasic dyskinesias, and peak-dose dyskinesias, though overlap is frequent.

    Conclusions:

    • Synaptic plasticity in striatal neurons is a suspected major contributor to LID.
    • Accurate classification and assessment of dyskinesias remain challenging.
    • Further research is needed to clarify the precise mechanisms and improve management strategies for LID.